1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 114 results.

$Thumbnail for CD20ΧCD3 Bispecific Antibodies in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Systematic Review$

ABCL - 324

CD20ΧCD3 Bispecific Antibodies in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Systematic Review

Anamika Adib

Poster Presenter: Anamika Adib

Thumbnail for BTK Inhibitors Combined With High-Dose Methotrexate-Based Induction in Newly Diagnosed Primary CNS Lymphoma: A Systematic Review and Meta-Analysis

ABCL - 325

BTK Inhibitors Combined With High-Dose Methotrexate-Based Induction in Newly Diagnosed Primary CNS Lymphoma: A Systematic Review and Meta-Analysis

Anamika Adib

Poster Presenter: Anamika Adib

Thumbnail for Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

ABCL - 346

Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

Sagar Patel

Poster Presenter: Sagar Patel

Thumbnail for Therapeutic Architecture Rather Than Population Differences Drives Frontline Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts

ABCL - 397

Therapeutic Architecture Rather Than Population Differences Drives Frontline Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts

Adarsh Vardhan Tangella

Poster Presenter: Adarsh Vardhan Tangella

Thumbnail for Impact of COVID-19 on Hematologic Malignancy Mortality: A Comparative Analysis of Pre-COVID (2015-2019) and COVID-Era (2020-2023) US Death Rates

ABCL - 399

Impact of COVID-19 on Hematologic Malignancy Mortality: A Comparative Analysis of Pre-COVID (2015-2019) and COVID-Era (2020-2023) US Death Rates

Madho Mal

Poster Presenter: Madho Mal

ABCL - 408

Obesity and Outcomes After Bone Marrow Transplant in Patients With Lymphoma: A Real-World TriNetX Study

Nayanika Tummala

Poster Presenter: Nayanika Tummala

$Thumbnail for Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups$

ABCL - 438

Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups

Jason Westin

Poster Presenter: Jason Westin

ABCL - 443

Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies

Mark Meerson

Poster Presenter: Mark Meerson

$Thumbnail for Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO$

ABCL - 483

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO

Haifaa Abdulhaq

Poster Presenter: Haifaa Abdulhaq